Statistics from Altmetric.com
The quality of quadrivalent human papillomavirus vaccine (QHPV) safety studies has been a source of conflict within the Cochrane Collaboration. The establishment of its safety for the young girl target age group has been a source of unease in other sectors including those with an interest in ovarian safety. Academic rigour and integrity in medical journal publications is guarded by editorial and peer-reviewed processes. The observation, however, that medical journals are at risk of becoming arms of the pharmaceutical industry1 highlights an increased scientific need for alert and active critique of industry-funded trials. Where biased publications are identified around one product there is perhaps a greater cause for concern.
A problem identified by the Cochrane conflict is that internal validity and generalisability of published drug trials need more probing than afforded by current systematic analyses. Cochrane2 confirms the limitations of using vaccine components as controls, since these components may be important to safety analysis. The importance of correctly identifying all placebo components is also just this. The Cochrane QHPV review and its critique,3 however, did not identify the misrepresentation of safety trials’ control constituents in published Future I and Future II trials. Both trials represent their controls as ‘aluminum hydroxyphosphate sulfate’. However Future I,4 Future II5 and Villa et al’s6 published trials passing both Cochrane’s inclusion standards …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.